INTRODUCTION {#S2}
============

An inflammatory microenvironment is a critical component driving tumorigenesis, from cancer initiation to metastasis to end-stage treatment-resistant lethal disease ([@R5]; [@R17]; [@R31]; [@R55]). In many adult tissues, cancers originate in sites of chronic inflammation ([@R4]). It is hypothesized that sustained proliferative signals from inflammatory cells can cooperate with oncogenic events to promote tumorigenesis ([@R8]). Mouse models have been developed that recapitulate features of inflammation in the tumor microenvironment and demonstrate a role for defined immune cell types and inflammatory cytokines in cancer initiation and progression ([@R1]; [@R10]). Few studies have investigated the functional consequences of inflammation in human epithelial tissues.

Chronic inflammation of the prostate is a risk factor for aggressive prostate cancer ([@R17]; [@R44]; [@R45]), as men with chronic inflammation in benign tissues have greater than double the risk for developing high-grade disease compared to men with no inflammation in their benign biopsy cores ([@R17]). Groundbreaking work from De Marzo and colleagues has defined a series of histological changes associated with chronic inflammation in the human prostate known as proliferative inflammatory atrophy (PIA) as a likely precursor for prostate cancer ([@R6], [@R8]). In PIA, the luminal epithelial layer in close proximity to infiltrating immune cells is described as having an atrophic appearance with an increased proliferative index, suggesting a regenerative response ([@R7]). Luminal cells associated with PIA exhibit reduced androgen signaling and increased expression of the anti-apoptotic factor BCL2 ([@R6], [@R7]). PIA cells are thought to exhibit an intermediate state of differentiation between basal and luminal cells and are predicted to serve as target cells in prostate tumorigenesis ([@R51]). Several groups have modeled inflammation in the mouse prostate using a variety of approaches, including bacterial infection ([@R9]; [@R26]; [@R28]), high-fat diet ([@R29]), and adoptive transfer of prostate-targeting T cells ([@R18]), demonstrating that prostatic inflammation is associated with increased epithelial proliferation. However, mouse models may not recapitulate the complex environment of aged human prostate tissues exposed to chronic inflammation for years prior to the development of prostate cancer ([@R17]).

Lineage tracing in the mouse has demonstrated that both basal and luminal cells are sufficient to initiate prostate cancer following *Pten* deletion, with differences in tumor outcome depending on the genetic background and status of *Nkx3-1* ([@R3]; [@R32]; [@R53]). Luminal cells can initiate murine prostate cancer in diverse genetically engineered mouse models ([@R54]), while purified basal cells can respond to a range of oncogene combinations to generate murine tumors using a tissue-regeneration approach ([@R30]). In the human prostate, we and others have demonstrated that basal cells isolated from benign human prostate can give rise to tumors following oncogenic transformation ([@R12]; [@R48]; [@R50]). To date, luminal cells in the human prostate have only been shown to initiate indolent-like tumors with limited proliferation ([@R37]), perhaps due to the low rate of proliferation among luminal cells ([@R6]). In contrast, luminal cell proliferation is increased in regions associated with inflammation in human prostate ([@R6]), suggesting that luminal cells isolated from regions with inflammation may exhibit progenitor cell features and give rise to aggressive prostate cancer.

Here, we report that expression of the luminal cell marker CD38 is heterogeneous in the human prostate. We used low expression of CD38 to isolate a subset of p63-negative, keratin 14 (K14)-negative, keratin 18 (K18)-positive luminal cells from primary benign human prostate with unique functional and molecular properties compared to CD38^hi^ luminal cells. Human prostate CD38^lo^ CD38^lo^ luminal cells are expanded in regions with inflammation, express markers of PIA, and are enriched for progenitor activity. In human tissues, CD38 is inversely correlated with prostate cancer progression and low CD38 mRNA in tumors is prognostic for biochemical recurrence and metastasis. Finally, CD38^lo^ luminal cells can initiate prostate cancer in response to oncogenic transformation using a human tissue regeneration model in immune-deficient mice. These collective results support inflammation-associated luminal cells as a target cell for aggressive prostate cancer.

RESULTS {#S3}
=======

Differential Expression of CD38 Enables Isolation of Two Distinct Luminal Subsets {#S4}
---------------------------------------------------------------------------------

CD38 is reported as a marker of luminal cells in the human prostate ([@R27]), and gene expression studies demonstrate that CD38 mRNA can distinguish basal from luminal cells ([@R46]). We measured cell-surface expression of CD38 by flow cytometry and confirmed that within the EpCAM^+^ CD45^−^ epithelial fraction, CD38 is expressed by CD26^+^ luminal cells, but not by CD49f-hi basal cells ([Figure 1A](#F1){ref-type="fig"}). Upon performing immunohistochemical staining for CD38 in human prostate tissue, we noted heterogeneous staining within the luminal layer, including areas where CD38 expression was reduced within individual glands ([Figure 1B](#F1){ref-type="fig"}).

We set out to viably isolate luminal cells based on variations in surface expression of CD38 using fluorescence-activated cell sorting (FACS). After removing CD45^+^ immune cells and gating on EpCAM^+^ epithelial cells, we observed three cell populations based on expression of CD49f and CD38 ([Figure 1C](#F1){ref-type="fig"}) in preparations of dissociated cells isolated from benign human prostate tissue. Intracellular flow cytometry revealed that both CD49f-lo CD38^hi^ and CD49f^lo^ CD38^lo^ subsets expressed high levels of the luminal marker K18 ([Figures 1D](#F1){ref-type="fig"} and [S1A](#SD1){ref-type="supplementary-material"}). Western blot analysis demonstrated that basal markers p63 and K14 are not expressed in either luminal subset ([Figure 1E](#F1){ref-type="fig"}). We noted elevated expression of keratin 5 (K5), a marker of a proposed intermediate-type luminal cell ([@R51]), in CD38^lo^ compared to CD38^hi^ luminal cells ([Figure S1B](#SD1){ref-type="supplementary-material"}). Following cell isolation, cell diameters were measured to examine differences in size among the three epithelial populations. CD38^lo^ luminal cells demonstrated an average diameter intermediate between basal and CD38^hi^ luminal cells ([Figure 1F](#F1){ref-type="fig"}). These findings indicate that CD38 stratifies luminal cells into two distinct subpopulations. Importantly, CD38^lo^ luminal cells do not express CD26 by flow cytometry ([Figure S1C](#SD1){ref-type="supplementary-material"}). These data indicate that CD38^lo^ luminal cells are distinct from CD26^+^ luminal cells and represent a population not previously investigated in prior studies ([@R25]; [@R37]; [@R48]).

CD38^lo^ Luminal Cells Are Enriched for Progenitor Activity Compared to CD38^hi^ Luminal Cells {#S5}
----------------------------------------------------------------------------------------------

In order to test the functional capacity of distinct luminal subsets, it is important to remove any potential contaminating basal cells that are highly clonogenic in progenitor assays ([@R11]; [@R25]; [@R37]). We used a double-sorting approach to isolate highly purified preparations of CD38^lo^ and CD38^hi^ luminal cells from benign human prostate tissue and confirmed an absence of basal cells based on lack of expression of CD49f ([Figure 2A](#F2){ref-type="fig"}) and p63 ([Figures S2A and S2B](#SD1){ref-type="supplementary-material"}). In a two-dimensional colony-forming assay and a three-dimensional sphere-forming assay ([@R30]; [@R33]), CD38^lo^ luminal cells exhibited progenitor activity intermediate between the highly clonogenic basal cells and the CD38^hi^ luminal cells ([Figures 2B and 2C](#F2){ref-type="fig"}). In a culture system adapted for the growth of human prostate-like tissue in vitro ([@R25]), CD38^lo^ luminal cells were highly (4- to 5-fold) enriched for organoid formation compared to CD38^hi^ luminal cells ([Figure 2D](#F2){ref-type="fig"}). CD38^lo^ luminal cell-derived organoids contained cells expressing both basal (K5 and p63) and luminal (K8) markers ([Figures 2E](#F2){ref-type="fig"} and [S2C](#SD1){ref-type="supplementary-material"}), similar to what has been reported for CD26^+^ luminal cells ([@R25]). When double-sorted cells were plated at single-cell density and visually confirmed, 5% (9/177) of single CD38^lo^ luminal cells were capable of generating organoids ([Figure 2F](#F2){ref-type="fig"}), which is considerably greater than the rate of CD38^hi^ luminal cells (1/142) and the 1% rate reported for CD26^+^ luminal cells ([@R25]; [@R37]).

CD38^lo^ Luminal Cells Exhibit an Inflammatory Signature {#S6}
--------------------------------------------------------

To investigate potential mechanisms regulating differential progenitor activity, we performed RNA sequencing (RNA-seq) and microarray analysis. We generated an RNA-seq signature comprised of 449 genes greater than 2 fold-enriched in CD38^lo^ luminal cells compared to CD38^hi^ luminal cells and greater than 1.5-fold enriched compared to basal cells ([Table S1](#SD2){ref-type="supplementary-material"}). We found that CD38^lo^ luminal cells express elevated levels of BCL2, a gene previously associated with PIA ([@R6]) ([Figure 3A](#F3){ref-type="fig"}). A number of inflammatory-related genes including cytokines (*Tnf*, *Il6*, and *Il8*) and chemokines (*Cxcl1*, *Cxcl2*, *Cxcl3*, *Cxcl6*, *Ccl2*, and *Ccl20*) are enriched in CD38^lo^ luminal cells ([Figure 3A](#F3){ref-type="fig"}). We performed pathway analysis using DAVID Bioinformatics ([@R22]) and found the most significant keywords included "inflammatory signaling" and "immune response" ([Figure 3B](#F3){ref-type="fig"}). The significant pathways and inflammatory-related genes were confirmed to be upregulated in CD38^lo^ luminal cells by microarray analysis. We confirmed activation of the nuclear factor κB (NF-κB) pathway at the protein level based on phosphorylated p65 and expression of BCL2 by western blot ([Figure 3C](#F3){ref-type="fig"}). In tissue sections, we found that phosphorylated p65 was highly expressed in CD38^lo^ luminal cells in a pattern inversely correlated with CD38 ([Figure 3D](#F3){ref-type="fig"}). Ingenuity pathway analysis identified tumor necrosis factor alpha (TNF) as a likely upstream regulator of CD38^lo^ luminal cells. We confirmed that TNF is expressed in CD38^lo^ cells but absent from CD38^hi^ luminal cells by immunohistochemistry ([Figure S3A](#SD1){ref-type="supplementary-material"}), suggesting that TNF may activate NFkB signaling in CD38^lo^ cells. We observed a diminution of p65 phosphorylation and reduced expression of BCL2 in CD38^lo^ cells following treatment with the NF-κB pathway inhibitor ACHP ([Figure S3B](#SD1){ref-type="supplementary-material"}). In a functional assay, ACHP treatment blocked the organoid-forming progenitor activity of CD38^lo^ luminal cells to a greater extent than other epithelial subsets ([Figure S3C](#SD1){ref-type="supplementary-material"}).

CD38^lo^ Luminal Cells Are Expanded in Glands Adjacent to Inflammation {#S7}
----------------------------------------------------------------------

Based on their gene expression profiling, including genes associated with PIA and inflammation, we investigated expression of CD38 in regions containing inflammatory infiltration ([Figure 3E](#F3){ref-type="fig"}). Staining for CD38 and CD45 on serial slides indicates that CD38 expression is reduced adjacent to CD45^+^ cells ([Figure 3F](#F3){ref-type="fig"}). We stained for a panel of immune cell subsets and found evidence of CD4^+^ and CD8^+^ T cells, CD11c^+^ and CD68^+^ myeloid cells, and CD20^+^ B cells adjacent to regions of the gland with low expression of CD38 ([Figure S3D](#SD1){ref-type="supplementary-material"}). In order to better define the relationship between CD38 expression and inflammation, we stratified glands into three categories: normal, inflamed, and atrophic, as classified by an expert pathologist. Inflamed glands were identified by pathologic criteria and confirmed with CD45 staining. Atrophic glands were identified by pathologic criteria and generally measured less than 20 μm from the basement membrane to the lumen in contrast to normal glands ([Figure S3E](#SD1){ref-type="supplementary-material"}). Loss of CD38 expression was measured in 95% (38/40) of inflamed glands, 88% (35/40) of atrophic glands, and only 10% (4/40) of normal glands from representative patient samples. Similar results were obtained for TNF, with strong expression in inflamed (38/40) and atrophic glands (33/40) with rare expression in normal glands (1/40). We further explored the connection between immune cells and CD38^lo^ luminal cells by flow cytometry in benign human prostate tissues from 29 distinct patient samples. We found a statistically significant association between the percentage of CD45^+^ immune cells and the proportion of luminal cells exhibiting a CD38^lo^ surface phenotype ([Figures 3G](#F3){ref-type="fig"} and [S3F](#SD1){ref-type="supplementary-material"}).

Reduced Androgen Signaling in CD38^lo^ Luminal Cells {#S8}
----------------------------------------------------

CD38^lo^ luminal cells express lower levels of *Klk3*, the gene for prostate-specific antigen (PSA) and other androgen-target genes (*Klk2*, *Klk4*, *Msmb*, *Acpp*, and *Fkbp5*) ([Figure 3A](#F3){ref-type="fig"}), consistent with reduced androgen signaling observed in PIA lesions ([@R6]). Similar results were observed by microarray analysis. qPCR confirmed differences in *Klk3* mRNA between the luminal subsets ([Figure 4A](#F4){ref-type="fig"}). In contrast, levels of the luminal gene K8 were not significantly different ([Figure 4A](#F4){ref-type="fig"}). Using immunohistochemistry, we confirmed diminished expression of androgen targets PSA, FKBP5, and MSMB in CD38^lo^ luminal cells at the protein level ([Figure 4B](#F4){ref-type="fig"}). Androgen receptor (AR) target NKX3-1 was also reduced in CD38^lo^ luminal cells ([Figure S4](#SD1){ref-type="supplementary-material"}). We hypothesized that low androgen signaling in CD38^lo^ luminal cells may be due to low levels of AR. While AR is expressed in CD38^lo^ cells, protein levels are reduced compared to CD38^hi^ luminal cells ([Figures 1E](#F1){ref-type="fig"} and [4C](#F4){ref-type="fig"}).

CD38^lo^ Luminal Phenotype Is Associated with Disease Progression and Poor Outcome {#S9}
----------------------------------------------------------------------------------

CD38 expression was previously reported to be reduced in a small cohort of prostate cancer specimens compared to benign prostate tissues ([@R27]). We examined expression of CD38 in a tissue microarray containing tissue cores from 267 patients with prostate cancer ([@R14]) ([Table S2](#SD2){ref-type="supplementary-material"}) and found the highest protein expression of CD38 in benign glands, with reduced expression in PIN and prostate cancer ([Figures 5A and 5B](#F5){ref-type="fig"}; [Table S3](#SD2){ref-type="supplementary-material"}). The lowest expression of CD38 was found in the most advanced tumors based on Gleason grade ([Figures 5A and 5B](#F5){ref-type="fig"}). Immunohistochemical staining was verified using two different anti-CD38 antibodies ([Figure S5](#SD1){ref-type="supplementary-material"}). While the average CD38 expression level was statistically significantly associated with time to biochemical recurrence, CD38 expression in cancer specimens was not statistically significant ([Table S4](#SD2){ref-type="supplementary-material"}).

Using the Memorial Sloan Kettering Cancer Center (MSKCC) dataset ([@R20]; [@R49]), we found that low CD38 mRNA in prostatectomy-derived prostate cancer samples is prognostic for biochemical recurrence and metastasis ([Figures 5C and 5D](#F5){ref-type="fig"}) in a statistically significant manner ([Table S5](#SD2){ref-type="supplementary-material"}). Importantly, low CD38 mRNA status is statistically significantly associated with both biochemical recurrence and metastasis after correction for Stephenson nomogram score ([@R47]), which includes both clinical and pathological variables ([Table S5](#SD2){ref-type="supplementary-material"}). Low CD38 mRNA is also prognostic for biochemical recurrence in the Cancer Genome Atlas (TCGA) dataset ([@R36]) ([Figure 5E](#F5){ref-type="fig"}). Upon stratifying tumors based on genotype, we found that low CD38 mRNA expression was associated with SPINK1 outlier status, but not ETS-related gene (ERG) rearrangements, in the MSKCC cohort ([Figure S6A](#SD1){ref-type="supplementary-material"}).

To determine whether the CD38^lo^ luminal gene signature could provide value in predicting patient survival, we turned to a Swedish watchful waiting cohort containing outcome data for 281 men ([@R43]). The mean of the scaled expression values of the CD38^lo^ luminal genes was significantly (p = 0.037) associated with all-cause mortality after adjusting for Gleason sum, age, and cancer percentage ([Table S6A](#SD2){ref-type="supplementary-material"}). When we analyzed the patients most at risk for prostate cancer-related mortality, with a Gleason score greater than or equal to 7 and follow-up within 5 years, we found a statistically significant difference (p = 0.007) between patients whose expression values lie in the top third (CD38^lo^ luminal-like) versus all others ([Figure S6B](#SD1){ref-type="supplementary-material"}; [Table S6C](#SD2){ref-type="supplementary-material"}). The statistical significance of the CD38^lo^ signature within this restricted group reached p = 0.0007 after adjusting for Gleason sum, age, and cancer percentage ([Table S6B](#SD2){ref-type="supplementary-material"}). The CD38^lo^ luminal gene signature is inversely correlated with the AR signature score ([@R19]) in prostate tumor specimens in a statistically significant manner in multiple cohorts ([Figure S6C](#SD1){ref-type="supplementary-material"}). We confirmed that the effect of the CD38^lo^ signature was independent of the AR signature ([@R19]; [@R35]) and a previously reported immune signature ([@R24]) ([Tables S6D and S6E](#SD2){ref-type="supplementary-material"}).

CD38^lo^ Luminal Cells Express the Therapeutic Target PSCA {#S10}
----------------------------------------------------------

While CD38 expression is low in the most aggressive tumors, we reasoned that genes in the CD38^lo^ luminal cell signature may be expressed in advanced disease and might serve as positive markers of this cell population. We used immunohistochemistry to investigate expression of prostate stem cell antigen (PSCA), a therapeutic target expressed in aggressive, metastatic, and castration-resistant prostate cancer ([@R16]). *Psca* is enriched in CD38^lo^ cells ([Figure 3A](#F3){ref-type="fig"}) but has not been previously associated with PIA. In tissue sections, PSCA expression was observed more commonly in inflamed (28/40) glands than atrophic (15/40) or benign (12/40) glands, in an expression pattern inversely correlated with CD38 ([Figure 6A](#F6){ref-type="fig"}). In some regions, these two markers can distinguish benign glands (CD38^hi^ PSCA-low) from cancer (CD38^lo^ PSCA-hi) ([Figure 6B](#F6){ref-type="fig"}). We hypothesized that CD38^lo^ PSCA-hi cancers may arise from the transformation of CD38^lo^ PSCA-hi luminal cells.

CD38^lo^ Luminal Cells Can Regenerate Glands and Initiate Human Prostate Cancer {#S11}
-------------------------------------------------------------------------------

To determine the functional capacity of CD38^lo^ luminal cells in tissue-regeneration and disease-initiation, we turned to an in vivo regeneration assay where human prostate epithelial cells are combined with urogenital sinus mesenchyme cells (UGSM) in Matrigel and transplanted subcutaneously into immune-deficient mice ([@R12], [@R13]). To track human epithelial cells, we introduced genes for red and green fluorescent proteins into CD38^lo^ luminal cells prior to in vivo transplantation ([Figures 7A](#F7){ref-type="fig"} and [S7A](#SD1){ref-type="supplementary-material"}). Due to low cell numbers insufficient for direct in vivo implantation, we utilized a recently published approach to expand isolated cells in organoid culture for 1--2 weeks prior to transplantation ([@R37]). An average of 200 lentiviral-transduced organoids derived from CD38^lo^ luminal cells were combined with UGSM and implanted into NOD-SCID-IL2Rγ^null^ mice. 8 weeks post-transplantation, we identified prostatic glands containing both luminal cells expressing K8 and AR and basal cells expressing K5 and p63 ([Figure 7B](#F7){ref-type="fig"}). Lentiviral transduced human epithelial structures in regenerated tissues could be identified based on fluorescent signal, whereas control grafts without human cells lacked any epithelial structures or fluorescence ([Figure S7C](#SD1){ref-type="supplementary-material"}).

Oncogenes previously shown to transform primary human prostate ([@R12]; [@R48]) (Myc, myristoylated AKT, and AR) were introduced into double-sorted CD38^lo^ luminal cells via lentiviral delivery prior to in vitro expansion and in vivo transplantation. We identified features of human prostate adenocarcinoma, including expression of the luminal markers K8, PSA, and AR and an absence of the basal markers K5 and p63 in regenerated tumors derived from oncogene-expressing CD38^lo^ luminal cells ([Figure 7C](#F7){ref-type="fig"}). Regenerated tumors exhibited expression of oncogenes ([Figure S7B](#SD1){ref-type="supplementary-material"}). Importantly, tumors exhibited the PSCA-hi CD38^lo^ luminal phenotype and a high frequency of cells expressed the proliferative marker Ki67 (\>40% Ki67^+^) ([Figure 7C](#F7){ref-type="fig"}). Results were confirmed using tissue from four independent patient samples. These findings indicate that CD38^lo^ luminal cells can initiate human prostate cancer in vivo.

DISCUSSION {#S12}
==========

Chronic inflammation is associated with cancer initiation, progression, metastasis, and treatment resistance in a range of tumor types including prostate cancer ([@R5]; [@R17]; [@R31]; [@R55]). In mouse models, several groups have established a tumor-promoting functional contribution of distinct immune cell types to prostate cancer, including B cells and myeloid-derived suppressor cells ([@R1]; [@R10]). However, little is known about the influence of inflammation on the function of human prostate epithelium prior to tumor formation. De Marzo and colleagues have proposed that inflammation may be an inciting event in prostate transformation and that PIA cells may serve as target cells for tumor initiation ([@R6], [@R7], [@R8]). Our results demonstrate that PIA-like CD38^lo^ luminal cells can initiate human prostate cancer.

Several groups have isolated human prostate luminal cells based on low expression of CD49f or high expression of CD26 for functional studies ([@R12]; [@R25]; [@R37]; [@R48]). We found that CD26 and CD38 identify an analogous population of prostate luminal cells ([Figure S1C](#SD1){ref-type="supplementary-material"}). While rare cells within the CD26^+^ or CD38^hi^ luminal cell population exhibit organoid-forming activity, \~99% of cells in this subset do not exhibit progenitor features ([Figures 2B--2D](#F2){ref-type="fig"}; [@R25]; [@R37]). In contrast, CD38^lo^ luminal cells are enriched for progenitor activity in 2D and 3D progenitor assays, as 5% of CD38^lo^ luminal cells are capable of generating organoids ([Figure 2D](#F2){ref-type="fig"}), similar to the rate of *Lgr5*-GFP-hi intestinal stem cells ([@R42]). Therefore, identifying the signaling pathways active in CD38^lo^ luminal cells may yield mechanisms regulating luminal progenitor activity.

We found that CD38^lo^ and CD38^hi^ luminal cells have distinct transcriptional signatures. While androgen signaling is active in CD38^hi^ luminal cells ([Figure 4](#F4){ref-type="fig"}), CD38^lo^ luminal cells exhibit elevated NF-κB signaling ([Figure 3](#F3){ref-type="fig"}). Previous studies demonstrate that NF-κB activation can synergize with MYC overexpression or *Pten* heterozygosity to accelerate murine prostate cancer initiation and the NF-κB activation signature in human tumors can predict poor outcome ([@R2]; [@R24]). These data suggest that NF-κB activity may predispose CD38^lo^ luminal cells to tumor initiation. More work is necessary to determine whether strategies to reduce inflammation or small molecules that block epithelial NF-κB signaling can prevent prostate cancer initiation by targeting CD38^lo^ luminal cell survival and progenitor activity.

CD38^lo^ luminal cells express PSCA, which is being evaluated as a therapeutic target in clinical trials using monoclonal antibodies ([@R34]). BCL2 expression in CD38^lo^ luminal cells may enhance their resistance to apoptosis ([@R40]). Both BCL2 and PSCA are associated with castration resistance ([@R16]; [@R40]), suggesting that CD38^lo^ luminal cells may have a survival advantage under low-androgen conditions. Consistent with mouse models demonstrating that prostatic inflammation or epithelial NF-κB activation is associated with reduced androgen signaling and increased epithelial proliferation ([@R2]; [@R26]), CD38^lo^ luminal cells express low levels of PSA and other androgen targets. These data suggest that CD38^lo^ luminal-like cancer cells may contribute to castration-resistant prostate cancer.

Distinguishing indolent from aggressive prostate cancer remains a critical goal of the field. We found that low expression of CD38 mRNA in prostatectomy specimens is prognostic for biochemical recurrence in two independent cohorts ([Figures 5C--5E](#F5){ref-type="fig"}). These data suggest that aggressive tumors may arise in CD38^lo^ luminal cells that retain low expression of CD38. Alternatively, the activation of a CD38^lo^ luminal-like signature during tumorigenesis may promote an aggressive phenotype, regardless of the cell of origin. Several studies have looked at the cellular origins of cancer to distinguish indolent from aggressive prostate cancer with different results using distinct mouse models ([@R3]; [@R32]; [@R52], [@R53], [@R54]). In human prostate models, basal cells have been shown to generate aggressive, highly proliferative tumors, while luminal cells can initiate only indolent tumors ([@R12]; [@R37]; [@R48]). In this study, we demonstrate that CD38^lo^ luminal cells can generate highly proliferative prostate cancer (\>40% Ki67+). Taken together, we hypothesize that one target cell (basal) is predisposed to the initiation of aggressive cancer under normal conditions. In the context of chronic inflammation, a second target cell (CD38^lo^ luminal) is predisposed to initiate aggressive cancer, perhaps due to elevated NF-κB signaling.

CD38^lo^ luminal cells may arise from basal to luminal differentiation, as has been demonstrated using lineage tracing in mouse models of inflammation ([@R28], [@R29]). Alternatively, inflammation may alter the differentiation of luminal cells by enhancing NF-κB signaling and reducing androgen signaling. Future studies will determine whether exposure to inflammatory cytokines can reprogram CD38^hi^ luminal cells into a progenitor-enriched CD38^lo^ luminal-like cell capable of initiating aggressive prostate cancer. Interestingly, CD38^lo^ luminal cells express cytokines and chemokines known to recruit pro-inflammatory cells and promote tumorigenesis in other tissues like *Ccl2* ([@R39]) and *Cxcl1/2* ([@R23]), indicating that CD38^lo^ luminal cells may influence their microenvironment to promote inflammation and maintain proliferative cues.

Our findings are consistent with previous reports of low CD38 expression in prostate cancer ([@R27]; [@R38]). While rare deletions and mutations of CD38 can be identified in metastatic castration-resistant prostate cancer ([@R15]; [@R41]), transcriptional repression of CD38 is the likely mechanism causing low expression in the vast majority of prostate tumors. CD38 is an ectoenzyme that consumes the cofactor nicotinamide adenine dinucleotide (NAD) ([@R21]), suggesting that loss of CD38 may serve to increase pools of NAD required for cellular metabolism in prostate cancer. Further study of the functional role of CD38 in tumorigenesis and the cellular mechanisms driving CD38^lo^ luminal cells may yield new predictive markers and therapeutic targets for aggressive disease.

EXPERIMENTAL PROCEDURES {#S13}
=======================

qPCR, RNA Sequencing, Bioinformatics, and Microarray {#S14}
----------------------------------------------------

RNA was extracted from cell pellets using the RNeasy mini Kit (QIAGEN/SA Biosciences). qPCR was carried out as previously described ([@R12]) using commercial primers to *Gapdh*, *Keratin 8*, and *Klk3* (QIAGEN/SA Biosciences). RNA-seq libraries were prepared with the Ovation RNA-Seq System V2 (Nugen). Double-stranded cDNA was generated with a mixture of random and poly(T) priming, followed by fragmentation, generation of blunt ends by end repair, A-tailing, ligation of adaptors (different adaptors for multiplexing samples), PCR amplification, and sequencing (pair read 100 run) on Illumina HiSeq 2500. Illumina SAV was used for data quality check, and Illumina CASAVA 1.8.2 was used for de-multiplexing. Reads were mapped to the most recent UCSC transcript set with Bowtie2 version 2.1.0. RSEM v1.2.15 was used to estimate level of gene expression. Gene expression was normalized by TPM (transcript per million) or RPKM (reads per kilobase per million mapped reads). DeSeq was used to identify differentially expressed genes. FASTQ files were not available at the time of publication. For that reason, the full RPKM values are provided in [Table S1](#SD2){ref-type="supplementary-material"}. Upstream regulator analysis was performed using QIAGEN's Ingenuity Pathway Analysis (<http://www.ingenuity.com>). For microarray analysis, total RNA was isolated from sorted cells with RNeasy Micro Kit and amplified with NuGen Pico kit according to standard manufacturer protocols. Biotinylated cDNA were prepared from total RNA using the standard Affymetrix protocol and hybridized to the Affymetrix Human Genome U133 Plus 2.0 Chip. Chips were scanned using an Affymetrix GeneChip Scanner 7G and data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings and global scaling as normalization method. Data are available at the GEO repository under accession number GEO: GSE89050.

Primary Cell Preparation and Cell Separation {#S15}
--------------------------------------------

Human prostate tissue samples were provided in a de-identified manner deemed by the institutional review board to not qualify as human subjects. Tissue was provided by the UCLA Translational Pathology Core Laboratory, and benign specimens were processed as described in detail previously ([@R13]). For antibody staining of primary benign dissociated cells, see [Supplemental Information](#SD1){ref-type="supplementary-material"}). Intracellular flow cytometry has been described previously ([@R12]). Antibodies are listed in [Supplemental Information](#SD1){ref-type="supplementary-material"}.

Immunohistochemical Analysis and Immunofluorescence {#S16}
---------------------------------------------------

Paraffin-embedded tissue sections were incubated in a 60°C oven for 1 hr and de-paraffinized in three changes of xylene, followed by 100% alcohol twice for 3 min each. Then the slides were transferred once in 95% and 70% alcohol, each for 3 min. A heat antigen retrieval step was used to unmask the antigenic epitopes. The remaining procedure was performed according to the manufacturer's protocol (R&D Cell and Tissue Staining Kit HRP-DAB system, R&D Systems). Primary antibodies are listed in [Supplemental Information](#SD1){ref-type="supplementary-material"}. Biotinylated anti-mouse and anti-rabbit secondary antibodies are supplied by HRP-DAB system for Mouse (CTS002, R&D Systems) and Rabbit Kit (CTS005, R&D Systems). Double-sorted cells were plated onto a glass slide coated with poly-L-lysine (Sigma), and cells were allowed to attach overnight. The following day, cells were fixed in 4% paraformaldehyde, washed three times in 1× PBS and stained with primary antibody. Alexa-488-conjugated goat anti-mouse secondary antibody (A-11001, Invitrogen) was used followed by DAPI nuclear counterstain (H-1200, Vector Laboratories).

Immunoblot Analysis {#S17}
-------------------

Isolated cell populations were lysed in RIPA buffer (150mM NaCl, 1% NP-40, 50 mM Tris-HCl \[pH 8.0\], 0.5% sodium deoxycholate, and 0.1% SDS) with protease inhibitor cocktail tablet (Complete, Roche) on ice 15 min followed by spin at maximum speed for 15 min. Supernatants were boiled in loading buffer and membranes probed with antibodies (see [Supplemental Information](#SD1){ref-type="supplementary-material"}). Primary rabbit, mouse, or goat antibodies were detected with horseradish peroxidase (HRP)-conjugated secondary antibodies (Pierce).

Tissue Microarray and Scoring {#S18}
-----------------------------

The tissue microarray was constructed from 332 men who underwent radical prostatectomy surgery at the West Los Angeles Veteran's Administration Hospital from 1991 to 2003 and has been described previously ([@R14]). At least three cores of each histological type are included per patient. Follow-up patient information for up to 120 months was used for analysis. Biochemical recurrence refers to PSA values greater than 0.2, two readings at 0.2, or additional treatment for high post-operative PSA. 4-μm sections were stained for CD38 and scanned using the Aperioslide scanner, and staining was evaluated in a blinded fashion by the pathologists (B.N. and J.H.). Scoring was assessed based on staining intensity from 0 (no staining) to 3 (strong) and percentage of tumor cell expression (1%--100%), creating a composite score from 0 to 300. For statistical methods, see [Supplemental Information](#SD1){ref-type="supplementary-material"}.

Cell Culture {#S19}
------------

For the in vitro organoid-forming assay, double-sorted FACS-isolated cell populations were plated in a 96-well plate (Corning Incorporated) at a cell density of one cell per well, and those wells with a single cell were visually confirmed and marked for continued analysis. Prostate organoid growth conditions were based on established protocols ([@R25]). Primary single-cell organoids were dissociated in 1 mg/mL Dispase (Gibco) at 37°C for 1 hr and then treated with 0.05% Trypsin-EDTA (Life Technologies) in order to passage. For the colony assay, primary cells were plated on Matrigel-coated six-well dishes as described previously ([@R33]) and grown in PrEGM media. Colonies containing more than two cells were quantified after 10--14 days. For the sphere assay, cells were resuspended in a PrEGM/Matrigel mixture and plated around the edges of the well in a 12-well dish as described previously ([@R33]). Spheres were quantified after 10--14 days. For inhibition of NF-κB, ACHP (4547, Tocris) was added to organoid media at a final concentration of 5 μM every 3 days.

In Vivo Regeneration and Transformation and Animal Care {#S20}
-------------------------------------------------------

In vivo tissue-regeneration and transformation methods have been described in detail ([@R13]). Transduced cells were expanded in organoid culture ([@R25]) prior to transplantation as described previously ([@R37]). All human tissues were transplanted subcutaneously into NOD-SCID-IL2Rγ^null^ mice. Animals have been purchased from the Jackson Laboratory and are now housed and bred under the care of the Division of Laboratory Animal Medicine at the University of California, Los Angeles, using protocols approved by the Animal Research Committee. Lentiviral vectors were previously described ([@R12]; [@R48]).
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![Differential Expression of CD38 Enables Isolation of Discrete Luminal Subsets from Fresh Human Prostate Tissue\
(A) Fluorescence-activated cell sorting analysis of dissociated benign human prostate cells demonstrates CD38 expression in EpCAM^+^ CD45^−^ CD26^+^ luminal cells, but not in EpCAM^+^ CD45^−^ CD49f-hi basal cells.\
(B) Immunohistochemical analysis of benign human prostate glands stained with anti-CD38 antibodies. Boxed region is magnified in the right. Arrows identify rare CD38^lo^ cells lining the gland. Scale bars, 50 μm.\
(C) Fluorescence-activated cell sorting analysis of dissociated benign human prostate cells gated on EpCAM^+^ CD45^−^ cells and further stained with antibodies against CD49f and CD38.\
(D) Intracellular flow cytometry for Keratin 18 (K18) and surface staining for CD38 and CD49f. Gating on K18^+^ luminal cells demonstrates two luminal populations in right plot.\
(E) Western blot analysis of three epithelial subsets from representative patient sample stained with antibodies against CD38, AR, p63, keratin 14 (K14), and histone H3 as a loading control.\
(F) Sorted cells were counted in a hemocytometer, and average cell diameter (in microns) was quantified for each population from multiple patient samples.\
Data represent mean ± SEM with replicate points shown. Newman-Keuls multiple comparison test with \*\*\*p \< 0.0001.](nihms852463f1){#F1}

![CD38^lo^ Cells Exhibit Greater Progenitor Activity than CD38^hi^ Luminal Cells In Vitro\
(A) Flow cytometry analysis for CD49f and CD38 dissociated human prostate epithelium as gated during the sort (left), and post-sort analysis of CD38^lo^ and CD38^hi^ luminal cells prior to in vitro culture.\
(B and C) Primary human benign prostate epithelial cells (EpCAM^+^ CD45^−^) were sorted into basal cells, CD38^lo^ and CD38^hi^ luminal subsets and plated for in vitro colony and sphere forming assays. Results from in vitro two-dimensional colony-forming assay (B) and three-dimensional sphere-forming assay (C) measured 10--14 days after plating benign human prostate epithelial subsets. Data represent pooled experiments from three independent patients. Mean ± SEM is shown. Statistics represent Newman-Keuls multiple comparison test with \*p \< 0.05, \*\*\*p \< 0.0005. Representative images of outgrowths from each epithelial subset are taken at 10--14 days. Scale bars, 250 μm.\
(D) CD38^lo^ luminal cells generate significantly more organoids than CD38^hi^ luminal cells, four replicates per sample, representative of five independent patient samples. Statistics represent Two-tailed unpaired t test with \*\*\*\*p \< 0.0001.\
(E) Representative staining of CD38^lo^ luminal cell-derived organoids for K5, K8, and DAPI nuclear counterstain. Scale bars, 50 μm.\
(F) Representative images of organoids forming from single CD38^lo^ luminal cells taken at day 1 and day 10. Scale bars, 100 μm.](nihms852463f2){#F2}

![CD38^lo^ Luminal Cells Are Associated with Inflammation\
(A) Heatmap of RNA-sequencing results of CD38^lo^ luminal cells and CD38^hi^ luminal cells from three independent patients.\
(B) DAVID bioinformatics analysis (SP_PIR\_ KEYWORDS) of the CD38^lo^ luminal gene signature with log(10) p values plotted.\
(C) Western blot analysis of CD38^lo^ and CD38^hi^ luminal cells from a representative benign human prostate sample stained for total p65, phosphorylated p65 (P-p65 S536), BCL2, and histone H3 as a loading control.\
(D) Immunohistochemical analysis of benign human prostate stained for CD38 and phosphorylated p65 (S536) on serial sections indicating an inverse relationship between expression of CD38 and P-p65. Scale bars, 50 μm.\
(E) Immunohistochemical analysis of benign human prostate glands stained with anti-CD38 antibodies. Boxed regions are magnified in the bottom row. Arrows denote regions of epithelium with low expression of CD38 in close proximity to red asterisk identifying areas with immune cell infiltration. Scale bars, 100 μm.\
(F) Immunohistochemistry on serial slides stained for CD38 and CD45. Scale bars, 100 μm.\
(G) Increased proportion of luminal cells with CD38^lo^ phenotype from 29 samples plotted as CD45^+^ cells less than or greater than 7% of total prostate. Statistics represent two-tailed t test; \*\*\*p = 0.0003.](nihms852463f3){#F3}

![CD38^lo^ Luminal Cells Exhibit Reduced Androgen Signaling\
(A) Relative expression of *Klk3* or *K8* compared to *Gapdh* in basal cells as measured by qPCR of basal, CD38^lo^, and CD38^hi^ luminal cells isolated from three independent patient samples. Data are presented as mean ± SEM with replicate points shown. *Klk3* is shown on a log scale. Two-tailed unpaired t test between CD38^lo^ and CD38^hi^ luminal subsets; \*\*\*p = 0.0004.\
(B) Immunohistochemical analysis of benign human prostate stained for CD38 and AR targets PSA, FKBP5, and MSMB. Scale bars, 100 μm.\
(C) Immunohistochemistry for CD38, PSA, and AR distinguishes CD38^hi^ and CD38^lo^ regions. AR expression is magnified to demonstrate reduced expression in CD38^lo^ cells. Scale bars, 50 μm.](nihms852463f4){#F4}

![Association of CD38^lo^ Phenotype with Prostate Cancer Progression\
(A) Plot of composite CD38 staining score in tissues histologically classified as normal, prostate intra-epithelial neoplasia (PIN), or prostate cancer (CA) with Gleason scores less than 7 or 7--10. Middle bar represents mean value. The overall effect of different levels of CD38 among the prostate regions was confirmed (p \< 0.001).\
(B) Representative immunohistochemical images of normal, PIN, Gleason 6, and Gleason 8 cancer stained for CD38, with high-power images below. Scale bars, 50 μm.\
(C and D) Survival analysis from MSKCC cohort measuring biochemical recurrence (C) and metastasis (D) for tumors containing CD38 mRNA 1 SD below the mean compared to the remainder (non-CD38^lo^). Log rank (Mantel Cox) p \< 0.001 (recurrence in C) and p = 0.002 (metastasis in D).\
(E) Survival analysis from the TCGA cohort measuring biochemical recurrence comparing CD38 expression less than (CD38^lo^) or greater than (non- CD38^lo^) the mean *Z* score. Log rank (Mantel Cox) p = 0.001.](nihms852463f5){#F5}

![PSCA Is Expressed in CD38^lo^ Luminal Cells\
(A) Serial sections of benign human prostate stained for CD38 and PSCA with boxed regions to magnify distinct CD38^hi^ PSCA-lo glands and inflammation-associated CD38^lo^ PSCA-hi cells.\
(B) Serial sections of human prostate tissue stained for CD38 and PSCA with boxed region magnifying CD38^hi^ PSCA-lo benign tissue separated by a dotted line from CD38^lo^ PSCA-hi cancer. Scale bars, 50 μm.](nihms852463f6){#F6}

![CD38^lo^ Luminal Cells Can Generate Glands and Initiate Human Prostate Cancer In Vivo\
(A) Schematic representing experimental flow where CD38^lo^ luminal cells are transduced with lentivirus, expanded in vitro 7--10 days, combined with UGSM and Matrigel and implanted in vivo. Regenerated tissues from representative experiments are shown on the right. Scale bars, 5 mm.\
(B) Representative in vivo regeneration of CD38^lo^ luminal cell-derived organoids transduced with control fluorescent GFP and red fluorescent protein (RFP) stained for H&E, K5, K8, DAPI nuclear counterstain, AR, and p63. Scale bars, 50 μm.\
(C) Representative adenocarcinoma in regenerated tumor tissues from CD38^lo^ luminal cells transduced with Myc, AKT, and AR stained for H&E, K5, K8, DAPI nuclear counterstain, AR, p63, Ki67, PSA, PSCA, and CD38. Scale bars, 25 μm.](nihms852463f7){#F7}

###### Highlights

-   Low expression of CD38 enriches for luminal progenitor cells in human prostate

-   CD38^lo^ luminal cells are localized in proximity to prostatic inflammation

-   CD38^lo^ luminal cells are target cells for aggressive human prostate cancer

-   Low CD38 in prostate cancer is prognostic for biochemical recurrence and metastasis
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